Statins and the risk of bleeding in patients taking dabigatran

Abstract

Objectives

Dabigatran etexilate is a direct thrombin inhibitor that clinicians increasingly prescribe to prevent stroke in patients with nonvalvular atrial fibrillation (NVAF). Clinicians also commonly prescribe statins for primary and secondary prevention of cardiovascular diseases. Little is known about the bleeding risk in patients taking a statin and dabigatran together. The aim of this study was to evaluate the safety and persistence of dabigatran after co‐medication with statins.

Materials & Methods

We performed a prospective, multicenter registry study of stroke patients with NVAF who initiated dabigatran therapy within 3 months after a clinically evident ischemic cerebrovascular event between 2013 and 2017. The main outcome measure was symptomatic bleeding after 90, 180, and 360 days.

Results

In total, 652 patients (336 statin users, 316 non‐users) were followed for one year after dabigatran therapy. Cox multivariate analysis demonstrated that male sex, prior use of aspirin, and concurrent use of an antiarrhythmic drug were associated with a higher risk of bleeding at 360 days. After adjusting time‐dependent covariates, statin users had a significantly lower bleeding risk (adjusted hazard ratio: 0.11, p < 0.001) than non‐users. Kaplan‐Meier analysis indicated that patients prescribed with statins had a higher rate of bleeding‐free survival (p = 0.028).

Conclusion

For secondary prevention of stroke in patients with NVAF who are taking dabigatran etexilate, co‐prescription with a statin was associated with a lower risk of bleeding complications. Future research is needed to determine the pharmacological mechanism underlying this effect.

This article is protected by copyright. All rights reserved.

http://bit.ly/2SJ1wdf